ArticleFrontiers in cell and developmental biology2025
Maternal and fetal outcomes in 151 cases of thrombocytopenia in pregnancy.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombocytopenia in Pregnancy: Clinical Challenges, Maternal-Fetal Risks, and Management Strategies.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thrombocytopenia during pregnancy is one of the important causes of maternal and perinatal mortality. This study aims to retrospectively analyze the clinical data of 151 pregnant patients with thrombocytopenia, in order to help obstetricians better understand the etiology, related risk factors and maternal and fetal outcomes of this disease. Methods: A total of 151 cases of pregnant women with thrombocytopenia were collected. According to the cause of thrombocytopenia, patients were divided into gestational thrombocytopenia (GT) group, hypertensive disorders in pregnancy (HDP) group, immune thrombocytopenia (ITP) group and the other group. According to the degree of thrombocytopenia, patients were divided into mild group, moderate group and severe group. According to different grouping criteria, the clinical characteristics, delivery outcomes and delivery modes, maternal treatments during pregnancy, maternal laboratory indexes, and neonatal birth conditions were compared. Results: Among the 151 patients, the GT group had the largest proportion. Moreover, the ITP group had a higher proportion of skin and mucous membrane bleeding during pregnancy, the smallest gestational age at first diagnosis and the lowest platelet count at first diagnosis. The treatment effect of glucocorticoids alone in the ITP group was not good. The HDP group had a higher neonatal intensive care unit (NICU) transfer rate and the lowest birth weight in newborns. In terms of severity, majority of the patients were in the mild group. The parameters of thromboelastography (TEG) were related to the pre-delivery platelet count of patients in the moderate and severe groups, but not in the mild group. Conclusion: In conclusion, ITP is associated with more severe thrombocytopenia and bleeding, often presenting in the early stage of pregnancy. In the treatment of ITP, the combined use of glucocorticoids and platelet transfusion is recommended. TEG parameter analysis suggests that patients in the moderate and severe groups may have changes in the blood coagulation and fibrinolysis systems. More attention should be paid to the monitoring of the newborns delivered by HDP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.